Our focus is on advanced anti-infective drugs that deactivate infections without exerting bactericidal effects. We target critical and unmet medical challenges like Hospital Acquired Infections (HAIs) and drug-resistant bacterial infections, such as Methicillin-resistant Staphylococcus aureus (MRSA).
Our groundbreaking research centers around Sortase A, a validated drug target in gram-positive bacteria. We have made significant progress in understanding the sortase A dimerization and its potential as a drug target, opening new avenues for drug discovery. Additionally, we have identified mammalian surface proteins that interact with sortase A, offering a unique opportunity for developing preventive anti-infective drugs.
Through our Biotech + TechBio platform, we pioneer rapid drug discovery and optimization. In Biotech, we utilize ex-vivo bacterial invasion assays and high throughput screening to identify promising drug candidates. We also employ gene editing technology to engineer cell lines for evaluating protein, peptide, and antibody-based drugs. In TechBio, we leverage AI capabilities in the fields of machine vision and generative BIOAI to accelerate drug discovery and optimize protein structures.
With our integrated approach, we deliver transformative solutions for gram-positive bacterial infections, ensuring precision and efficiency in drug design and therapeutic development.